- Houdini Bio has secured round £1.5 million in grants and pre-seed funding, with SCVC main the funding.
- The corporate’s software program adjustments therapeutic DNA so {that a} affected person’s personal cells don’t flip it off.
- In response to the startup, this resolution can enhance gene expression by greater than ten instances in comparison with opponents.
Houdini Bio simply raised about £1.5 million by combining non-dilutive grants, which don’t require giving up fairness, with an oversubscribed pre-seed spherical.
SCVC, the enterprise arm of Science Creates, led the spherical, whereas Deep Science Ventures and Cambridge Enterprise VC on the College of Cambridge additionally participated, in accordance with the corporate. Houdini Bio develops software program that redesigns therapeutic DNA so the physique’s defences don’t assault it.
The physique’s defence system is on the coronary heart of this story. A protein complicated referred to as HUSH usually confuses the DNA utilized in gene and cell therapies with a virus and turns it off. Because of this therapies that achieve trials can lose effectiveness in real-world use.
“Mobile equipment nonetheless rejects these therapies, limiting long-term effectiveness and forcing pricey, unsafe doses. Our platform introduces an important shift from trial-and-error screening to repeatable, engineering-driven DNA design,” Jonathan Cohen-Gold, Houdini Bio’s chief government, says.
The monetary stakes are excessive. The global gene therapy market is expected to grow from $10.04 billion in 2026 to $25.89 billion by 2031, in accordance with Mordor Intelligence. Nevertheless, this development has been accompanied by years of excessive manufacturing prices and disputes over reimbursement, making sturdiness one of many trade’s costliest and unresolved challenges.
A Cambridge discovery sparked this innovation
Cohen-Gold found the molecular workaround throughout his PhD on the College of Cambridge, constructing on Professor Paul Lehner’s identification of the HUSH complicated.
He co-founded Houdini Bio with Lee Dunham, the chief enterprise officer, who spent over ten years working with greater than 100 cell and gene remedy firms as a director on the Cell and Gene Remedy Catapult. Dunham has seen firsthand why promising therapies generally fail.
Based in 2025, the startup makes use of machine studying to analyse a remedy’s genetic sequence earlier than it reaches sufferers. This helps predict which DNA variations can bypass HUSH’s defences and stay lively.
For instance, a CAR-T remedy, which re-engineers a affected person’s immune cells to struggle most cancers, usually loses energy inside weeks as a result of the inserted gene is silenced. With Houdini Bio’s method, such therapies may keep lively longer at decrease, safer doses.
Many firms are racing to enhance sturdiness
Houdini Bio isn’t the one firm targeted on sturdiness. nChroma Bio, created when Chroma Medication merged with Nvelop Therapeutics in December 2024, raised $75 million led by Cormorant Asset Administration, ARCH Enterprise Companions, Atlas Enterprise and Newpath Companions. On the identical time, Dyno Therapeutics, primarily based in Cambridge, Massachusetts, makes use of AI to unravel a special downside: engineering the viral shells that ship gene therapies into cells.
Whereas these firms deal with supply strategies or silencing illness genes, Houdini Bio believes the hot button is within the DNA sequence itself. The corporate says its method will increase gene expression greater than tenfold over present main strategies, primarily based by itself preclinical knowledge.
“Gene therapies actually do characterize the way forward for medication, however they’re caught behind an invisible business and organic bottleneck,” says Harry Destecroix, SCVC’s managing associate. He has expertise on this space, having co-founded Ziylo, a Bristol spinout that Novo Nordisk acquired in 2018 for as much as $800 million. SCVC’s broader portfolio additionally contains deep-tech spinouts reminiscent of Delta g, Scarlet Therapeutics, and Isomab.
The corporate says that is Houdini Bio’s first public funding spherical, with all three named backers being new traders. No valuation was shared. Houdini Bio experiences that it reached its technical milestones in only a third of the anticipated time and plans to make use of the funds to develop its workforce and type co-development partnerships with pharmaceutical firms.
